A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine. The investigators demonstrated for the first time that antibodies to a toxin secreted from bacteria in acne vulgaris can reduce inflammation in human acne lesions. The lead investigator form Department of Dermatology, University of California explained o nce validated by a large-scale clinical trial, the potential impact of our findings is huge for the hundreds of millions of individuals suffering from acne vulgaris.
Current treatment options are often not effective or tolerable for many of the 85 percent of adolescents and more than 40 million adults in the United States who suffer from this multi-factorial cutaneous inflammatory condition. New, safe, and efficient therapies are sorely needed. Even though acne is not a…
